6825-71-4

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 3,5-diaMino-1H-pyrazole-4-carboxylate is used as a pharmaceutical intermediate for the synthesis of various drug compounds. Its unique structure allows it to serve as a building block in the development of new medications, potentially leading to the creation of novel therapeutic agents.
Used in Medical Experimental Research:
In the field of medical research, ethyl 3,5-diaMino-1H-pyrazole-4-carboxylate is utilized as a research tool to study the properties and interactions of carboxylic acid ester derivatives. This can help scientists better understand the mechanisms of action of related compounds and contribute to the advancement of medical knowledge and drug discovery.

Upstream product

• 121020-70-0 2-(cyanoethoxycarbonylmethylene)-1,3-dioxolane 
• 22071-00-7 1-Amino-1-trichlormethyl-2-carbethoxy-2-cyano-ethylen 
• 49765-05-1 (Z) 3-amino-4,4,4-trichloro-2-cyano-2-butenoic acid ethyl ester 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 74440-35-0 3,5-Diamino-1H-pyrazole-4-carboxylic acid hydrazide 
• 82819-89-4 3-phenylpropiolamido-4-ethoxycarbonyl-5-aminopyrazole 
• 82819-95-2 2-amino-3-ethoxycarbonyl-5-hydroxy-7-phenylpyrazolo<1,5-a>pyrimidine 

Relevant academic research and scientific papers

Alkyne derivative, preparation method and application thereof

The invention relates to an alkyne derivative and a preparation method thereof and application of the alkyne derivative in medicine, specifically to an alkyne derivative represented by general formula(I), a preparation method and a pharmaceutically accept

Larotinib derivative and preparation method and application thereof

The invention relates to a larotinib derivative and a preparation method and application thereof, and provides a novel larotinib derivative with anti-tumor activity. The novel larotinib derivative isbeneficial to improving the anti-tumor activity of the l

MACROCYCLE CONTAINING AMINOPYRAZOLE AND PYRIMIDINE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk.

MACROCYCLIC COMPOUNDS AND USES THEREOF

The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.

AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.

Neurotrophic factor tyrosine kinase receptor inhibitor

The invention provides a neurotrophic factor tyrosine kinase receptor inhibitor. The tyrosine kinase receptor inhibitor provided by the invention has a tricyclic parent core structure, can inhibit theactivity of Trk kinase and can be used for treating mammalian diseases mediated by the Trk kinase.

SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME

Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.

Substituted heteroaryl compounds and compositions and uses thereof

The invention discloses a substituted ceteroary compound as well as a composition and an application thereof. The compound is a compound shown in a formula (I) or a stereisomer, a tautomer, a nitric oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The invention further discloses a pharmaceutical composition including the compound. The compound and the pharmaceutical composition are capable of adjusting the activity of the AK kinase and can be used for preventing, processing, treating and relieving the JAK-mediated disease or disorder.

5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heterocyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.